Bullous pemphigoid in patients receiving peritoneal dialysis: a case series and a literature survey.
Bullous pemphigoid
hemodialysis
incidence
peritoneal dialysis
Journal
Renal failure
ISSN: 1525-6049
Titre abrégé: Ren Fail
Pays: England
ID NLM: 8701128
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
entrez:
6
4
2021
pubmed:
7
4
2021
medline:
11
11
2021
Statut:
ppublish
Résumé
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease. Although several cases of BP in end-stage renal disease patients receiving peritoneal dialysis (PD) or hemodialysis have been reported, the incidence of BP in these patients remains unknown. We recently experienced three PD patients diagnosed with BP. The skin injury was likely to be a trigger of BP in all the three PD patients. Nifedipine and icodextrin exposures were possible factors directly or indirectly affecting the onset of BP, because they were common in the three cases. We also report that the incidence of BP in PD patients was 3/478.3 person-years in a single-center 10-year study. This case series with a literature survey describes that the skin and tissue injuries are potential triggers responsible for the onset of BP in dialysis patients and that the incidence of BP in these patients seems to be much higher than that in the general population.
Identifiants
pubmed: 33820495
doi: 10.1080/0886022X.2021.1910045
pmc: PMC8032334
doi:
Substances chimiques
Autoantibodies
0
Icodextrin
2NX48Z0A9G
Nifedipine
I9ZF7L6G2L
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
651-657Références
Nat Rev Immunol. 2017 Jan;17(1):21-29
pubmed: 27916977
Hemodial Int. 2014 Apr;18(2):525-8
pubmed: 24165026
BMC Med. 2013 Apr 04;11:94
pubmed: 23556986
J Invest Dermatol. 2015 May;135(5):1445-1447
pubmed: 25560279
Clin Exp Dermatol. 2002 Jan;27(1):70-2
pubmed: 11952679
Surgery. 1998 Jul;124(1):112-3
pubmed: 9663262
J Invest Dermatol. 2020 Apr;140(4):733-741
pubmed: 32200875
J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1135-6
pubmed: 17714155
Case Rep Nephrol Dial. 2014 Oct 01;5(1):26-9
pubmed: 25849671
Immunol Lett. 2012 Mar 30;143(1):92-100
pubmed: 22305931
Autoimmun Rev. 2015 May;14(5):438-45
pubmed: 25617817
J Invest Dermatol. 2011 Mar;131(3):631-6
pubmed: 21085189
Clin J Am Soc Nephrol. 2017 Apr 3;12(4):687-693
pubmed: 28148557
Clin J Am Soc Nephrol. 2010 Aug;5(8):1410-9
pubmed: 20558560
Biomed Res Int. 2015;2015:416480
pubmed: 26064907
Case Rep Dermatol. 2020 Mar 17;12(1):42-46
pubmed: 32308574
Lancet. 2013 Jan 26;381(9863):320-32
pubmed: 23237497
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419863238
pubmed: 31280608
Int Wound J. 2017 Feb;14(1):288-292
pubmed: 27748034
Int Urol Nephrol. 2016 Apr;48(4):585-91
pubmed: 26762886
Eur J Dermatol. 2009 Sep-Oct;19(5):500-3
pubmed: 19502152
J Am Acad Dermatol. 2004 Aug;51(2 Suppl):S131-2
pubmed: 15280832
J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1133-40
pubmed: 24404939
J Allergy Clin Immunol. 2020 Apr;145(4):1031-1047
pubmed: 32272980
J Dermatol. 2016 Feb;43(2):134-40
pubmed: 26173987
An Bras Dermatol. 2015 May-Jun;90(3 Suppl 1):43-5
pubmed: 26312671
J Am Acad Dermatol. 2013 Jun;68(6):e192-3
pubmed: 23680218
Cell. 1981 Jun;24(3):897-903
pubmed: 7018697
Hemodial Int. 2018 Apr;22(2):E26-E32
pubmed: 29227569
Br J Dermatol. 1993 Nov;129(5):642-3
pubmed: 7902731
J Clin Invest. 1990 Oct;86(4):1088-94
pubmed: 1698819
J Dermatol. 1998 Apr;25(4):246-9
pubmed: 9609983